top of page

Murray B. Stein

Murray B. Stein


  • M.D.

  • MPH


Current Position(s): 

  • Vice Chair for Clinical Research in Psychiatry at UCSD

  • Staff Psychiatrist at VA San Diego Healthcare System

Personal Statement: 

Dr. Stein’s research interests include the epidemiology, neurobiology, and treatment of anxiety disorders especially social phobia, panic disorder, and posttraumatic stress disorder. He has written or co-written over 700 peer-reviewed scientific articles on these topics, including in journals such as JAMA, New England Journal of Medicine, The Lancet, American Journal of Psychiatry, and JAMA Psychiatry. His federally funded research has included studies of interventions for anxiety disorders in primary care, pharmacological approaches to treatment-resistant anxiety disorders, and functional neuroimaging research in anxiety and trauma-related disorders.

Professional History:

  • Co-Principal Investigator (with Robert Ursano MD) of Army STARRS, an NIMH-funded project (2009-2015) investigating risk factors for suicide, PTSD and other deployment-related disorders

  • STARRS-LS (2019-2023)

  • Executive Committee member for the multicenter TRACK-TBI Study (PI: Geoff Manley MD, PhD at UCSF)

  • Co-PI with Kerry Ressler MD PhD of a DoD-funded multi-site trial of losartan for PTSD (2015-2020)

  • Co-Principal Proponent (with Joel Gelernter MD) of a VA Cooperative Genomewide Association Study of PTSD (2013­2020), in conjunction with the VA Million Veteran Program

  • Member of the Scientific Advisory Board of the Anxiety and Depression Association of American (ADAA) (present)

  • Fellow of the American College of Neuropsychopharmacology (ACNP) (present)

  • Scientific Chair of the NIMH Interventions in Mood and Anxiety (ITMA) Review Group (2006-2009)

  • Member of the DSM-5 Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders Work Group (2009-2013)

  • Member of the National Academy of Medicine Board on the Health of Select Populations (2012-2015)

  • National Academy of Medicine Committee to Review NASA's Evidence Reports on Human Health Risks (2016)

  • Member of the Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) (2011-2016).


  • University of Manitoba in Bethesda, MD

  • Residency and post-residency fellowship at the University of Toronto and at the National Institute of Mental Health in Bethesda, MD

  • Master of Public Health degree at the Johns Hopkins University Bloomberg School of Public Health in Baltimore, MD


National/Global Website: National Center for Biotechnology Information

bottom of page